Tags

Type your tag names separated by a space and hit enter

[Thrombin induced tumour growth - pharmacological control].
Hamostaseologie. 2007 May; 27(2):105-10.H

Abstract

The central enzyme of blood coagulation, the serine proteinase thrombin, is capable to modify the growth of tumour cells by interaction with protease activated receptors 1 and 4 of the tumour cells. Thrombin is permanently available in tumour micro environment; meizothrombin is generated from prothrombin at a tumour specific activation complex and can influence tumour cell growth via PAR-1 and 7-transdomain protein receptor signalling pathway, too. PEG-coupled direct thrombin inhibitors that possess special pharmacokinetic characteristics and that have been designed for long lasting efficacy in extracellular space, control serine proteinase activity in tumour micro environment and therefore they own a high potential anti-tumour efficacy. In xenographic tumour models this new substance class has shown a significant carcinostatic effect.

Authors+Show Affiliations

AG Pharmakologische Hämostaseologie, Medizinische Fakultät, Friedrich-Schiller-Universität Jena, Drackendorfer Str. 1, 07747 Jena.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

ger

PubMed ID

17479173

Citation

Nowak, G, et al. "[Thrombin Induced Tumour Growth - Pharmacological Control]." Hamostaseologie, vol. 27, no. 2, 2007, pp. 105-10.
Nowak G, Lopez M, Zieger M. [Thrombin induced tumour growth - pharmacological control]. Hamostaseologie. 2007;27(2):105-10.
Nowak, G., Lopez, M., & Zieger, M. (2007). [Thrombin induced tumour growth - pharmacological control]. Hamostaseologie, 27(2), 105-10.
Nowak G, Lopez M, Zieger M. [Thrombin Induced Tumour Growth - Pharmacological Control]. Hamostaseologie. 2007;27(2):105-10. PubMed PMID: 17479173.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Thrombin induced tumour growth - pharmacological control]. AU - Nowak,G, AU - Lopez,M, AU - Zieger,M, PY - 2007/5/5/pubmed PY - 2007/8/2/medline PY - 2007/5/5/entrez SP - 105 EP - 10 JF - Hamostaseologie JO - Hamostaseologie VL - 27 IS - 2 N2 - The central enzyme of blood coagulation, the serine proteinase thrombin, is capable to modify the growth of tumour cells by interaction with protease activated receptors 1 and 4 of the tumour cells. Thrombin is permanently available in tumour micro environment; meizothrombin is generated from prothrombin at a tumour specific activation complex and can influence tumour cell growth via PAR-1 and 7-transdomain protein receptor signalling pathway, too. PEG-coupled direct thrombin inhibitors that possess special pharmacokinetic characteristics and that have been designed for long lasting efficacy in extracellular space, control serine proteinase activity in tumour micro environment and therefore they own a high potential anti-tumour efficacy. In xenographic tumour models this new substance class has shown a significant carcinostatic effect. SN - 0720-9355 UR - https://www.unboundmedicine.com/medline/citation/17479173/abstract/Thrombin_induced_tumour_growth___Pharmacological_control DB - PRIME DP - Unbound Medicine ER -